{"id":"W4378619580","doi":"10.3390/medicina59061041","title":"Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection","year":2023,"lang":"en","type":"review","venue":"Medicina","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug; Human immunodeficiency virus (HIV); Drug resistance; Rilpivirine; Multiple drug resistance; Virology; Pharmacology; Antiretroviral therapy; Viral load; Biology; Microbiology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008688585,0.0005627641,0.000979207,0.004096163,0.0003622936,0.001669747,0.0008163766,0.0009232611,0.0135924],"category_scores_gemma":[0.0017838,0.0002029579,0.001111073,0.006055272,0.0003121944,0.001460828,0.0004425329,0.0008561494,0.002389722],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007362401,"about_ca_system_score_gemma":0.002324665,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001506318,"about_ca_topic_score_gemma":0.002147551,"domain_scores_codex":[0.999504,0.00008037307,0.00008996241,0.00007095063,0.0002043921,0.00005042201],"domain_scores_gemma":[0.9990187,0.0004771615,0.0002019411,0.00001986796,0.0002301461,0.00005211552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001322713,0.00009635218,0.0003291668,0.09001426,0.0001747307,0.000773789,0.0002909164,0.0004746188,0.002680551,0.007703365,0.07307597,0.8242541],"study_design_scores_gemma":[0.00002516519,0.0001245846,0.0008765173,0.01619032,0.0003970666,0.001015247,0.0001168209,0.00009980326,0.0007413435,0.001668656,0.9787263,0.00001821665],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006251591,0.990046,0.0001929036,0.0008863282,0.0003955548,0.00003855259,0.0002607065,0.0000175875,0.007537175],"genre_scores_gemma":[0.002394195,0.9949379,0.0002470386,0.0005624329,0.0002695059,0.00002486028,0.0001954251,0.000003515113,0.001365043],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.0135924,"threshold_uncertainty_score":0.04547107,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06026421496698506,"score_gpt":0.3044588700438364,"score_spread":0.2441946550768513,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}